This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Coronary atherosclerosis
  • /
  • Cangrelor: Pharmacology, Clinical Data, and Role i...

Cangrelor: Pharmacology, Clinical Data, and Role in Percutaneous Coronary Intervention.

Read time: 1 mins
Published:1st Jan 2017
Author: Price MJ
Availability: Pay for access, or by subscription
Ref.:Interv Cardiol Clin. 2017;6(1):39-47

In clinical trials that assessed the safety and efficacy of cangrelor during percutaneous coronary intervention (PCI), cangrelor was administered as a 30-μg/kg bolus followed by a 4-μg/kg/min infusion for at least 2 hours or the duration of the PCI, whichever was longer.

Cangrelor is currently indicated as an adjunct to PCI to reduce the risk of myocardial infarction, repeat coronary revascularization, and stent thrombosis in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.


Read abstract on library site

Access full article